ALOGLIPTIN; METFORMIN HYDROCHLORIDE
Clinical safety rating: safe
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
Alogliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon. Metformin is a biguanide that decreases hepatic glucose production, improves insulin sensitivity, and reduces intestinal glucose absorption.
| Metabolism | Alogliptin is minimally metabolized, primarily via CYP2D6 (small contribution) and 3A4, but majorly excreted unchanged in urine. Metformin is not metabolized; excreted unchanged in urine via tubular secretion. |
| Excretion | Alogliptin: 76% renal, 13% fecal; Metformin: 90% renal unchanged. |
| Half-life | Alogliptin: 21 hours; Metformin: 6.4 hours (plasma) but prolonged in renal impairment. |
| Protein binding | Alogliptin: 20% (primarily albumin); Metformin: negligible (<5%). |
| Volume of Distribution | Alogliptin: 417 L (≈6.0 L/kg); Metformin: 654 L (≈9.4 L/kg), reflecting extensive tissue distribution. |
| Bioavailability | Alogliptin: 100% oral; Metformin: 40-60% oral (saturable absorption). |
| Onset of Action | Oral: Alogliptin 1–2 hours; Metformin 2 hours (glycemic effect). |
| Duration of Action | Alogliptin: 24 hours; Metformin: up to 24 hours (immediate-release) or >24 hours (extended-release). |
| Molecular Weight | Alogliptin: 339.4 Da; Metformin hydrochloride: 165.63 Da |
Oral: one tablet twice daily. Dose depends on prior antidiabetic regimen: initial alogliptin 12.5 mg/metformin 500 mg; maximum alogliptin 25 mg/metformin 2000 mg per day.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥60 mL/min/1.73m²: no adjustment; eGFR 30-59: maximum alogliptin 12.5 mg/day and metformin 1000 mg/day; eGFR <30: contraindicated. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B or C: not recommended due to metformin component. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Start at lower end of dosing range; assess renal function before initiation and monitor regularly; avoid in patients with eGFR <30 mL/min/1.73m² due to metformin. |
| 1st trimester | Metformin: Limited human data suggest no increased risk of major birth defects. Alogliptin: No adequate human data; animal studies show no teratogenicity at clinically relevant doses. Use only if potential benefit outweighs risk. |
| 2nd trimester | Metformin: Generally considered acceptable for treatment of gestational diabetes. Alogliptin: Avoid due to lack of human safety data and potential for fetal harm. |
| 3rd trimester | Metformin: Can cause neonatal hypoglycemia, but benefits may outweigh risks in gestational diabetes. Alogliptin: Avoid due to lack of human data and theoretical risk of neonatal hypoglycemia. |
Clinical note
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
| FDA category | Human |
| Placental transfer | Metformin crosses the placenta and achieves fetal concentrations similar to maternal. Alogliptin likely crosses the placenta based on animal studies; human data are lacking. |
■ FDA Black Box Warning
Lactic acidosis: Metformin increases risk of lactic acidosis, especially in patients with renal impairment, sepsis, hepatic impairment, alcohol abuse, or acute heart failure. Discontinue in patients with conditions that may cause hypoxia or with severe infections.
| Common Effects | Diarrhea |
| Serious Effects |
Renal disease or renal dysfunction (e.g., serum creatinine ≥1.5 mg/dL in males, ≥1.4 mg/dL in females, or abnormal creatinine clearance) for metformin componentAcute or chronic metabolic acidosis, including diabetic ketoacidosisHypersensitivity to alogliptin, metformin, or any component of the productType 1 diabetes mellitus
| Precautions | Lactic acidosis (discontinue with renal impairment, sepsis, hepatic impairment, alcohol abuse, acute heart failure, dehydration, or hypoxic conditions), Pancreatitis (discontinue if suspected), Hypoglycemia risk when used with insulin or sulfonylureas, Renal impairment (contraindicated if eGFR < 30 mL/min/1.73 m2; not recommended if eGFR 30-45 mL/min/1.73 m2), Hepatic impairment (avoid in significant liver disease), Vitamin B12 deficiency (monitor with long-term metformin use), Acute kidney injury (risk with contrast dye; withhold metformin), Hypersensitivity reactions (e.g., angioedema, anaphylaxis, severe cutaneous reactions) |
Loading safety data…
| Breastfeeding | Metformin is excreted into breast milk in low amounts; infant plasma levels are subtherapeutic. Alogliptin is excreted in animal milk; no human data. Use caution, especially in nursing infants with renal impairment. Monitor infant for hypoglycemia, diarrhea, and rash. |
| Lactation Rating | L3 (Moderately Safe) for Metformin; L4 (Possibly Hazardous) for Alogliptin |
| Teratogenic Risk | Alogliptin: FDA Pregnancy Category B. Animal studies show no evidence of teratogenicity, but no adequate human studies. Metformin: FDA Pregnancy Category B. Not associated with major malformations; limited data suggest no increased risk. First trimester: No known major teratogenic risk. Second and third trimesters: No documented fetal harm. However, metformin may reduce first-trimester miscarriage risk in PCOS. Overall risk considered low. |
| Fetal Monitoring | Maternal: Renal function (serum creatinine, eGFR) at baseline and periodically, as metformin is renally eliminated. Hepatic function. Blood glucose and HbA1c. Monitor for hypoglycemia. Lactic acidosis symptoms (rare with metformin). Fetal/neonatal: Ultrasound for growth and anomalies (standard care for diabetic pregnancies). Neonatal hypoglycemia risk if maternal glycemic control poor. |
| Fertility Effects | Alogliptin: No known direct effects on human fertility; animal studies show no impairment. Metformin: Improves ovulation and pregnancy rates in women with PCOS by reducing insulin resistance and hyperandrogenism. No adverse effects on male fertility; may improve sperm quality in men with metabolic syndrome. Overall, may enhance fertility in insulin-resistant states. |
| Food/Dietary | Avoid excessive alcohol intake (≥3 drinks/day) due to increased risk of lactic acidosis. Take with food to minimize gastrointestinal upset. No specific foods to avoid, but maintain consistent carbohydrate intake to optimize glycemic control. |
| Clinical Pearls | Monitor renal function before initiating therapy and periodically; contraindicated if eGFR <30 mL/min/1.73 m². Assess for lactic acidosis risk (e.g., sepsis, dehydration, hepatic impairment). ALOGLIPTIN; METFORMIN HYDROCHLORIDE is a DPP-4 inhibitor and biguanide combination; ensure patient is aware of signs of pancreatitis (severe abdominal pain) and hypoglycemia when used with insulin or sulfonylureas. Vitamin B12 levels should be monitored annually due to metformin's long-term use. Avoid in acute heart failure exacerbation. |
| Patient Advice | Take with meals to reduce gastrointestinal side effects. · Do not consume excessive alcohol while taking this medication. · Report symptoms of lactic acidosis (unusual tiredness, muscle pain, difficulty breathing, severe drowsiness, slow heart rate). · Monitor blood glucose regularly and know signs of hypoglycemia (shakiness, sweating, fast heartbeat). · Store at room temperature away from moisture and heat. · Do not stop taking abruptly; consult prescriber for dose adjustments. · May cause decreased vitamin B12 levels; report any numbness or tingling. |